팝업레이어 알림
RNA Trans-splicing Ribozyme-based gene therapy- RNA editing technology
has been identified as a
"national strategic technology
possessing/managing company
for advanced bio-gene and cell therapy"
in the 2nd National Strategic Technology Identification System!
This is another achievement
following the last "confirmation of national strategic research/development companies".
About Rznomics
Our vision is to treat/conquer various human intractable diseases such as hepatocellular carcinoma, intractable cancers, degenerative diseases and genetic diseases through development of innovative RNA-based biopharmaceutical.
About Rznomics
Excellence in Technology
-
Dual function in a single molecule
-
Modular Engineering
-
Disease-related RNA target specificity
-
High Performance
-
Continuous regulation of gene expression
Rznomics Pipeline
PIPELINE
Rznomics has core competencies to meet a variety of
unmet medical needs through development of
biopharmaceutical based on RNA platform
technology for cancer/intractable diseases.
NEWS & PRESS
Latest news about Rznomics or Stay informed about Rznomics
-
Rznomics Wins the Korea Innovation Startup Award led by K-Deep Tec...
Rznomics (CEO Seong-wook Lee, Graduate Bio-convergence Engineering Department) a subsidiary of the ...
-
Gene Therapy Is Developing Rapidly in the Asia Pacific
The Asia-Pacific gene therapy market was valued at $349.1 million in 2020 and is expected...
-
Rznomics gets approves U.S. FDA For anticancer Candidate Based On ...
Rznomics gets approves U.S. FDA For anticancer Candidate Based On Gene Therapy RZ001+T-Sentric...
- Head Office#327, Software & ICT Hall, 152, Jukjeon-ro, Suji-gu, Yongin, 16890, Korea
- TEL. 031-706-8730
- FAX. 031-8018-8734
- E_mailrznomics@rznomics.com
- Research Institute and Pangyo branch office#801(Pangyo branch office), #803(Research Institute) Innovalley Bldg. C, 253, Pangyo-ro, Bundang-gu, Seongnam, 13486, Korea
- TEL. 031-706-8730
Copyright(C) 2019 Rznomics. All Rights Reserved.
